Supreme Continues to Strengthen Leadership Team for Growth

TSXV: FIRE

TORONTO, Jan. 8, 2018 /CNW/ - The Supreme Cannabis Company, Inc. ("Supreme" or the "Company") (TSXV: FIRE) is pleased to announce the addition of Ms. Sony Gokhale, BBA, LLB, as the Company's General Counsel.  Ms. Gokhale was most recently a senior member of the Commercial and Technology group at Osler, Hoskin & Harcourt, LLP in Toronto, Ontario. 

"Our business is driven by a commitment to quality. The quality of our products, the quality of our facility and, most of all, the quality of our leadership team," said John Fowler, CEO of Supreme.  "Since inception, Supreme has been focused on developing 7ACRES into a leading cultivator of premium cannabis flower for the domestic medical and recreational markets. The next chapter for Supreme is to identify and execute on opportunities to leverage our success with 7ACRES into additional business undertakings here in Canada and abroad. Supreme is pleased to welcome Ms. Gokhale to our team as we embark on this next chapter."

Prior to joining Supreme, Ms. Gokhale's practice included advising on general corporate and commercial matters with a focus on assisting regulated and non-regulated companies with the launch of new products and services in the Canadian market. Additionally, Ms. Gokhale has provided ongoing advice to leading Canadian and international companies on strategic commercial contracting issues. Prior to joining Osler, Ms. Gokhale was senior counsel for BlackBerry where she negotiated various complex offshore service and distribution agreements in over twenty countries.

The Company granted 500,000 stock options (each an "Option") to Ms. Gokhale pursuant to the Company's Amended and Restated Incentive Stock Option Plan (the "Plan"). Each Option has an exercise price of $3.05 and is exercisable into one common share , subject to certain vesting conditions and the terms and conditions of the Plan, and expire on January 7, 2023.

About Supreme

Supreme is a Canadian publicly traded company committed to becoming a leading cultivator and distributor of sun grown cannabis through its wholly-owned subsidiary 7ACRES. 7ACRES is a federally licensed producer of medical cannabis pursuant to the ACMPR operating inside a 342,000 sq. ft. Hybrid Greenhouse facility. The Hybrid Greenhouse combines the best technology of indoor production with the efficiencies and sustainability of a greenhouse, in a single large-format production footprint. Please visit www.supreme.ca and www.7acres.com for more information.

Forward-Looking Information

Certain statements made in this press release may constitute forward-looking information under applicable securities laws. These statements may relate to anticipated events or results and include, but are not limited to, all statements that are not historical facts. Particularly, information regarding our expectations of future results, targets, performance achievements, prospects or opportunities is forward-looking information. Often, but not always, forward-looking statements can be identified by the use of forward-looking terminology such as "may" "will", "expect", "believe", "estimate", "plan", "could", "should", "would", "outlook", "forecast", "anticipate", "foresee", "continue" or the negative of these terms or variations of them or similar terminology. Forward-looking statements are current as of the date they are made and are based on applicable estimates and assumptions made by us at the relevant time in light of our experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we believe are appropriate and reasonable in the circumstances. However, we do not undertake to update any such forward-looking information whether as a result of new information, future events or otherwise, except as required under applicable securities laws in Canada. There can be no assurance that such estimates and assumptions will prove to be correct.  Many factors could cause our actual results, level of activity, performance or achievements or future events or developments to differ materially from those expressed or implied by the forward-looking statements, including, without limitation, the factors discussed in the "Risks and Uncertainties" section of the Company's Management's Discussion & Analysis dated November 27, 2017 ("MD&A"). A copy of the MD&A and the Company's other publicly filed documents can be accessed under the Company's profile on SEDAR at www.sedar.com. The Company cautions that the list of risk factors and uncertainties described in the MD&A is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking information and are cautioned not to place undue reliance on such information.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Supreme Pharmaceuticals Inc.

Investor Relations, Jenni Byrne, Bayfield Strategy, Inc., Phone: [phone], Email: [email protected], Website: supreme.ca